Spero Therapeutics logo
Spero Therapeutics
SPRO | NASDAQ
Chart Builder DCF Calculator
$0.93
-$0.07 (-6.99%)
At close: Nov 16, 2026, 3:59 PM ET
$0.93
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Spero Therapeutics Company Profile

Company profile explained

Company Profile

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Key Executives

Name Position
Esther Rajavelu CEO, President, CFO, Chief Business Officer, Treasurer & Director
Timothy Keutzer Chief Operating Officer
Debra Jeske Zack Chief Medical Officer
John Raymond Senior Vice President of Finance & Business Operations
Sheila Finan Senior VP & Controller

Latest SEC Filings

Date Type Title
Oct 28, 2026 S-8 Filing
Oct 27, 2026 8-K Current Report
Sep 10, 2026 EFFECT Filing
Aug 28, 2026 8-K Current Report
Aug 28, 2026 S-3 Filing
Aug 12, 2026 8-K Current Report
Aug 12, 2026 10-Q Quarterly Report
Aug 06, 2026 4 Filing
Aug 06, 2026 3 Filing
Jul 14, 2026 8-K Current Report
View All SEC Filings ➞
Spero Therapeutics
Spero Therapeutics logo
Country United States
IPO Date Nov 2, 2017
Industry Biotechnology
Sector Healthcare
Employees 25
CEO Esther Rajavelu

Contact Details

675 Massachusetts Avenue Cambridge, Massachusetts 02139 United States

Stock Details

Ticker Symbol SPRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001701108
CUSIP Number 84833T103
ISIN Number US84833T1034
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.